logo
Blackstone Leads Bidding for $1 Billion AGS Health Deal

Blackstone Leads Bidding for $1 Billion AGS Health Deal

Bloomberg20-05-2025
Blackstone Inc. is emerging as the frontrunner to acquire revenue cycle management provider AGS Health from private equity firm EQT AB, people familiar with the matter said.
Blackstone has pulled ahead of other bidders and could reach a deal as soon as the coming days, the people said, asking not to be identified because the information is private. A transaction could value AGS Health at $1 billion or more, according to the people.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Elizabeth Warren Says Elon Musk's SpaceX Is Paying Less Tax Than You But Getting 'Billions' From The Government: Trump And GOP 'Rigged' The Tax Code
Elizabeth Warren Says Elon Musk's SpaceX Is Paying Less Tax Than You But Getting 'Billions' From The Government: Trump And GOP 'Rigged' The Tax Code

Yahoo

time9 minutes ago

  • Yahoo

Elizabeth Warren Says Elon Musk's SpaceX Is Paying Less Tax Than You But Getting 'Billions' From The Government: Trump And GOP 'Rigged' The Tax Code

Sen. Elizabeth Warren (D-Mass.) has accused Elon Musk's SpaceX of benefiting from billions in U.S. government contracts while paying little to no federal taxes. Warren Accuses Musk Of Dodging Taxes On Monday, Warren took to X, formerly Twitter, and said that "Elon Musk's SpaceX is worth over $350 BILLION – after receiving billions in government contracts – but could be paying LESS in taxes than you." She blamed Donald Trump's tax reforms, saying Republicans "rigged the tax code with loopholes for billionaire corporations" and demanded "no more corporate handouts." Trending: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — Her remarks followed a New York Times report that SpaceX has avoided paying federal income tax on about $5 billion in taxable income since its founding in 2002 by using a legal tax strategy known as a net operating loss carryforward. The provision, expanded indefinitely under Trump in 2017, lets companies offset future income with earlier losses. Musk Previously Defended Tesla's Tax Strategy Musk currently has a net worth of $375 billion, according to Bloomberg's Billionaire Index, making him the wealthiest individual on Earth. In February earlier this year, Musk and Tesla Inc. (NASDAQ:TSLA) VP of Finance Sendil Palani denied claims that Tesla evaded taxes, saying that the company legally carried forward past losses under IRS provisions. At the time, Musk acknowledged Tesla didn't pay U.S. federal income tax for several years, including 2024, since most profits come from overseas sales, but highlighted the need for comprehensive tax reform to address excessive Revenue Soars, Taxes Stay Low Documents reviewed by the publication show that more than 75% of SpaceX's revenue in 2020 and 2021 came from federal contracts. Despite that reliance on taxpayers, SpaceX paid only minimal taxes — including $483,000 to foreign governments and $78,000 in state taxes in 2021. SpaceX's business is also booming. Revenue is expected to reach $15.5 billion in 2025, double the $7.4 billion reported in 2023. Starlink, its satellite internet service, now generates more revenue than its rocket division, with 2.5 million users and $8 billion in 2023 sales. Warren Broadens Criticism Of Musk Warren has previously also targeted Musk over what she describes as conflicts of interest and misuse of government influence. In June, her office released a report titled "130 Days of Elon Musk," alleging more than 100 abuses of power during his time as a Trump administration adviser. She has also criticized the Pentagon for awarding Musk's AI startup xAI a $200 million contract just days after its chatbot Grok was caught making antisemitic remarks. Read Next: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom Photo Courtesy: Sheila Fitzgerald On UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Elizabeth Warren Says Elon Musk's SpaceX Is Paying Less Tax Than You But Getting 'Billions' From The Government: Trump And GOP 'Rigged' The Tax Code originally appeared on Sign in to access your portfolio

Better Quantum Computing Stock: D-Wave Quantum vs. Quantum Computing Inc.
Better Quantum Computing Stock: D-Wave Quantum vs. Quantum Computing Inc.

Yahoo

time9 minutes ago

  • Yahoo

Better Quantum Computing Stock: D-Wave Quantum vs. Quantum Computing Inc.

Key Points Quantum computing offer an intriguing opportunity given its potential to revolutionize many industries. D-Wave Quantum and Quantum Computing Inc. are early-stage businesses with promising innovations. However, both companies are seeing volatile sales across quarters, and neither is profitable. 10 stocks we like better than D-Wave Quantum › The quantum computing sector offers an exciting new area to invest in. Quantum machines can perform sophisticated calculations beyond the capabilities of current classical computers. This tech could transform industries such as medicine and artificial intelligence. But among the bevy of businesses in the field, which are worthwhile long-term investments as the nascent industry grows? Two to consider are D-Wave Quantum (NYSE: QBTS) and Quantum Computing Inc. (NASDAQ: QUBT), which also refers to itself as QCi. Between D-Wave and QCi, one looks like the better quantum computing stock. Read on for an exploration of both businesses to understand which one and why. Untangling D-Wave Quantum's business performance D-Wave produces income primarily through subscriptions to its quantum systems via the cloud and professional services to support customers in the use of its technology. In 2025, D-Wave's sales have been on a roller coaster. It generated $15 million in the first quarter after selling one of its quantum computers. In Q2, revenue was $3.1 million, a 42% increase from 2024's $2.2 million as the company picked up $1 million to upgrade the device sold in the first quarter. This sales volatility could continue for some time as D-Wave grows its business. An encouraging sign is 92% year-over-year growth in its Q2 bookings to $1.3 million. Bookings represent customer orders received in the quarter that are expected to produce revenue when the orders are fulfilled. However, D-Wave isn't turning a profit. Its Q2 operating loss of $26.5 million was a 42% increase from the previous year. That's a concerning trend given its Q2 revenue of just $3.1 million. Fortunately, D-Wave has stockpiled a record high $819.3 million in cash and equivalents on its balance sheet. It exited Q2 with total assets of $843.6 million versus total liabilities of $149.3 million. This enables the company to maintain operations in the short term on its path to revenue growth. Quantum Computing Inc.'s budding business QCi uses light particles, called photons, to perform calculations in its quantum computer chips. It sells these chips, other hardware, and professional services to generate revenue. The company is in an early stage of its business lifecycle with sales coming primarily from research grants and proof-of-concept projects. As a result, its sales are small, and prone to substantial swings. For example, in 2024, QCi generated revenue of $373,000, a 4% year-over-year increase. But through the first half of 2025, sales plunged 52% to $100,000. QCi's technology has the potential to generate long-term revenue growth. Photons can be used in a wide range of light sensing, imaging, and other optical applications. Nevertheless, until QCi can gain traction with a larger group of customers, sales will continue to struggle. And that does not bode well for its business viability, because the company is not profitable. The company exited Q2 with an operating loss of $10.2 million against revenue of $61,000 as research and development costs more than doubled year over year to $6 million. QCi's saving grace is that, like D-Wave, it amassed a large war chest to fund operations in the short term. Q2 total assets were $426.1 million with cash and equivalents of $348.8 million. Total liabilities in the quarter were $30.1 million. Deciding between D-Wave Quantum and Quantum Computing Inc. In choosing between D-Wave Quantum or QCi, an important consideration is share price valuation. Since both are not profitable, the way to get at this is using the price-to-sales (P/S) ratio, which measures how much investors are willing to pay for every dollar of revenue generated over the trailing 12 months. The chart shows QCi's P/S multiple is far above D-Wave's, and the disparity is so great, QCi shares look overpriced. Consequently, D-Wave stock is the better value. This, combined with promising sales and bookings growth, makes D-Wave a more attractive investment than its rival. At QCi's current phase of development, it's a highly speculative stock given the low revenue, high costs, and limited commercial sales. This doesn't mean D-Wave shares are a bargain, since its sales multiple is quite high as well. Another factor to consider is that the quantum computing industry is in its early stages. Quantum computers are prone to calculation errors, because the atomic particles in these machines are sensitive to the slightest environmental disturbances, such as a minor temperature change. So while D-Wave is the better choice versus QCi, any investment in a pure-play quantum computer company is a risk. And it could take years before a scalable quantum device is possible. Some estimates predict that won't happen until 2040. Given these factors, only investors with a high risk tolerance should consider investing in D-Wave. Should you invest $1,000 in D-Wave Quantum right now? Before you buy stock in D-Wave Quantum, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and D-Wave Quantum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Better Quantum Computing Stock: D-Wave Quantum vs. Quantum Computing Inc. was originally published by The Motley Fool

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

Yahoo

time9 minutes ago

  • Yahoo

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ('Eton' or the 'Company') (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@ Source: Eton Pharmaceuticals. This press release was published by a CLEAR® Verified in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store